Pre-Market Stock Futures: Futures are trading lower after a wild day on Wall Street, as stocks took off after Treasury Secretary Bessent announced the Treasury would double its current bond buyback, targeting 10- to 20-year and 20- to 30-year maturities. That sparked an initial big rally, which tapered by the close; still, all of the ... Here Are Thursday’s Top Wall Street Analyst Research Calls: Alphabet, Analog Devices, Crown Castle, ebay, EPR Properties, Etsy, Merck & Co., Shopify, TJX Compan

Wolfe Research identified seven stocks combining strong earnings, rapid sales growth, and positive momentum in a tough market.

While Incyte has outperformed the broader market over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

On July 20, Halozyme Therapeutics, Inc. (NASDAQ:HALO) and Incyte Corporation (NASDAQ:INCY) announced a global collaboration and licensing deal to develop a subcutaneous formulation of Incyte’s INCA033989. The first-in-class monoclonal antibody targets mutant calreticulin (mutCALR)-expressing myeloproliferative neoplasms. By utilizing Halozyme’s proprietary ENHANZE drug delivery technology, INCY aims to create a more convenient dosing regimen for patients. […]

Biopharmaceutical company Incyte Corporation (INCY) gets Big Money support to gain 23% so far in 2026.

MIRM Q2 earnings miss estimates while revenues beat the same, as Livmarli and bile acid drugs fuel growth, prompting a higher 2026 sales outlook.

REGN vs. INCY: Which Stock Is the Better Value Option?

Incyte (INCY) is back in focus after the European Commission approved Opzelura cream for moderate atopic dermatitis in certain adults, shortly after the company reported second quarter results and raised full year sales guidance. See our latest analysis for Incyte. The recent European approval for Opzelura and the stronger second quarter results come after a period of firm momentum in Incyte’s stock, with a 90 day share price return of 23.33% and a 1 year total shareholder return of...

Incyte stock has delivered a strong run over the last three years, yet the broader valuation checks suggest it may no longer stand out as a clear bargain at current levels. Incyte has returned 87.8% over the past three years, which puts fresh focus on whether recent gains already reflect much of the good news. Recent approvals for Opzelura in atopic dermatitis and new partnership activity can support confidence in future revenue, while execution risk around expanding treatments and...

In July 2026, Incyte received European Commission approval for Opzelura (ruxolitinib) cream to treat moderate atopic dermatitis in adults who do not respond adequately to, or cannot use, topical corticosteroids and calcineurin inhibitors, supported by positive Phase 3 data showing improved symptoms, quality of life and tolerability. This second European indication for Opzelura, alongside strong Phase 3b TRuE-AD4 outcomes, highlights Incyte’s growing dermatology franchise and its ability to...

European Commission approves Opzelura (ruxolitinib) cream as the first steroid free topical JAK inhibitor for adults with moderate atopic dermatitis in the EU. Decision is based on Phase 3b TRuE AD4 data in adult patients with mild to moderate atopic dermatitis. Approval expands Opzelura's use in Europe and adds a new dermatology revenue opportunity for Incyte. For investors following Incyte, ticker NasdaqGS:INCY, this EU approval adds a fresh piece of news around its dermatology efforts...

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.

The European Commission on Wednesday approved Incyte’s Opzelura cream as the first steroid-free topical treatment of its kind for adults with moderate eczema who do not get enough relief from standard creams.

Incyte Corp (INCY) reports a 38% increase in total revenue, raises full-year guidance, and highlights significant advancements in its diverse product pipeline.

Incyte tops Q2 earnings and revenue estimates as Jakafi and Opzelura sales surged, prompting the company to raise its 2026 revenue outlook.

Incyte (NASDAQ:INCY) reported second-quarter 2026 net product sales of $1.49 billion, up 40% from a year earlier, supported by demand growth across its marketed portfolio and a one-time non-cash benefit tied to the resolution of a CMS matter involving OPZELURA. Excluding the $246 million one-time b

While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Incyte (NASDAQ:INCY) reported better-than-expected second-quarter earnings and revenue on Tuesday, although its shares edged lower in pre-market trading after the company issued full-year sales guidance that came in below analysts’ expectations. The biotechnology group delivered strong growth across its commercial portfolio, supported by higher sales from several key products and continued pipeline progress.

Incyte (INCY) delivered earnings and revenue surprises of +54.50% and +14.71%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 37.7% year on year to $1.67 billion. On the other hand, the company’s full-year revenue guidance of $5.20 billion at the midpoint came in 9.2% below analysts’ estimates. Its non-GAAP profit of $3.09 per share was 43.9% above analysts’ consensus estimates.

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting results this Tuesday before the bell. Here’s what to look for.

Incyte (NasdaqGS:INCY) reported full safety and efficacy results from its Phase 1/2 study of latarcibart, a once monthly subcutaneous therapy for von Willebrand disease. The company announced the acquisition of VGA039 (latarcibart) through the purchase of Vega Therapeutics to support further development. Latarcibart carries breakthrough, fast track, orphan drug, and rare pediatric disease designations. For investors tracking Incyte, this update sits at the intersection of rare disease drug...

INCY heads into Q2 earnings with strong Jakafi demand, Opzelura momentum and rising royalties, fueling expectations for an earnings beat.

LENZ Therapeutics, Inc. (LENZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Halozyme grants ENHANZE rights to Incyte for developing subcutaneous cancer therapy formulations, aiming to improve treatment convenience for patients.

Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Halozyme Therapeutics (NASDAQ:HALO) has entered into a global collaboration and license agreement with Incyte (NASDAQ:INCY) to support the development of subcutaneous formulations of INCA033989, expanding the use of its ENHANZE® drug delivery technology into another partnered program. Key Investor TakeawaysHalozyme signed a global collaboration and license agreement with Incyte centered on ENHANZE® drug delivery technology.

Get paid a guaranteed income on your Vertex shares today, which you keep no matter what, for agreeing to sell them at a higher price if the stock keeps climbing.

Incyte is scheduled to release its second-quarter results later this month, with analysts projecting a double-digit increase in its bottom line figure.

Incyte has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 8.6% to $114.25 per share while the index has gained 8.2%.

Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index rising 0.2% and

For investors seeking exposure to biotechnology's future, Incyte presents a clearer forward picture of accelerating growth, while the larger Regeneron asks for more faith in its pipeline.